Flora Growth Corp. (FLGC)
NASDAQ: FLGC · Real-Time Price · USD
10.15
-0.30 (-2.87%)
At close: Dec 5, 2025, 4:00 PM EST
9.95
-0.20 (-1.97%)
After-hours: Dec 5, 2025, 7:37 PM EST

Company Description

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide.

The company operates in two segments: Commercial and Wholesale, House of Brands. It cultivates, processes, and supplies medicinal-grade cannabis flower, as well as cannabis derived medical and wellness products.

The company also offers food and beverage, nutraceutical, cannabis accessories and technology, personal care, and wellness products; and cannabis consumption accessories, as well as personal storage and travel accessories for the vape and dry herbs.

In addition, it manufactures and distributes pharmaceutical goods and medical cannabis products to treat a range of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants.

Further, the company sells its products under the JustCBD, Vessel, and Phatebo brand names. Flora Growth Corp. was incorporated in 2019 and is headquartered in Fort Lauderdale, Florida.

Flora Growth Corp.
Flora Growth logo
Country United States
Founded 2019
IPO Date May 11, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 75
CEO Daniel Reis-Faria

Contact Details

Address:
3230 West. Commercial Boulevard, Suite 180
Fort Lauderdale, Florida 33309
United States
Phone 954 842 4989
Website floragrowth.com

Stock Details

Ticker Symbol FLGC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001790169
CUSIP Number 339764300
ISIN Number CA3397643006
SIC Code 2834

Key Executives

Name Position
Daniel Reis-Faria Chief Executive Officer and Director
Dany Vaiman Chief Financial Officer
Michael Heinrich Executive Chairman
Dr. Manfred Ziegler Managing Director
Patrick Moloney Head of Product Development
Aaron Atin Corporate Secretary

Latest SEC Filings

Date Type Title
Nov 28, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Nov 28, 2025 8-K Current Report
Nov 18, 2025 S-8 Securities to be offered to employees in employee benefit plans
Nov 5, 2025 10-Q Quarterly Report
Nov 4, 2025 DEF 14A Other definitive proxy statements
Oct 27, 2025 SCHEDULE 13D Filing
Oct 24, 2025 PRE 14A Other preliminary proxy statements
Oct 10, 2025 8-K Current Report
Oct 10, 2025 SCHEDULE 13D Filing
Oct 10, 2025 D Notice of Exempt Offering of Securities